Optimized anti-tumor effects of anthracyclines plus Vinca alkaloids using a novel, mechanism-based application schedule

Blood

Volumn 118, Issue 23, 2011, Pages 6123-6131

  Ehrhardt, Harald ^a,b   Schrembs, David ^a   Moritz, Christian ^a   Wachter, Franziska ^a   Haldar, Subrata ^c   Graubner, Ulrike ^b   Nathrath, Michaela ^a   Jeremias, Irmela ^a,b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DOXORUBICIN; PROTEIN BCL 2; PROTEIN P53; VINCA ALKALOID; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE ARREST; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 82955207718     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-02-269811     Document Type: Article

References (35)

1. Dy GK, Adjei AA. Systemic cancer therapy: evolution over the last 60 years. Cancer. 2008;113(7 suppl):1857-1887.
2. Frei E. Curative cancer chemotherapy. Cancer Res. 1985;45(12):6523-6537.
3. Ramaswamy S. Rational design of cancer-drug combinations. N Engl J Med. 2007;357(3):299- 300.
4. Frei E. Combination cancer therapy: presidential address. Cancer Res. 1972;32(12):2593-2607.
5. Frei E. Combination chemotherapy. Proc R Soc Med. 1974;67(6):425-433.
6. Goldin A, Johnson RK. Antitumor effect of adriamycin in comparison with related drugs and in combination chemotherapy. In: Staquet M, Tagnon H, Kenis Y, eds. Adriamycin Review. Ghent, Belgium: European Press Medikon; 1975:37-54.
7. Zeller WJ, Berger M, Schmähl D. Synergistic action of vincristine and adriamycin in the treatment of experimental rat leukemia L5222. Cancer Res. 1979;39(3):1071-1073. (Pubitemid 9135136)
8. Akutsu M, Furukawa Y, Tsunoda S, Izumi T, Ohmine K, Kano Y. Schedule-dependent synergism and antagonism between methotrexate and cytarabine against leukemia cell lines in vitro. Leukemia. 2002;16(9):1808-1817.
9. Kaspers GJL, Veerman AJP, Pieters R, van Zantwijk I, Hählen K, van Wering ER. Drug combination testing in acute lymphoblastic leukemia using the MTT assay. Leuk Res. 1995;19(3):175- 181.
10. Müller HJ, Boos J. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol. 1998; 28(2):97-113. (Pubitemid 28390409)
11. Mayer LD, Janoff AS. Optimizing combination chemotherapy by controlling drug ratios. Mol Interv. 2007;7(4):216-223. (Pubitemid 47437268)
12. Li T, Ling YH, Goldman ID, Perez-Soler R. Schedule- dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res. 2007;13(11):3413- 3422.
13. Barone C, Landriscina M, Quirino M, et al. Schedule- dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial. Br J Cancer. 2007; 96(1):21-28. (Pubitemid 46094634)
14. Bonadonna G, Zambetti M, Moliterni A, Gianni L, Valagussa P. Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and fluorouracil in operable breast cancer. J Clin Oncol. 2004;22(9):1614-1620. (Pubitemid 41079799)
15. Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes: ten-year results. JAMA. 1995;273(7):542- 547.
16. Valeriote F, van Putten L. Proliferation-dependent cytotoxicity of anticancer agents: a review. Cancer Res. 1975;35(10):2619-2630.
17. Benz EJ Jr, Nathan DG, Amaravadi RK, Danial NN. Targeting the cell death-survival equation. Clin Cancer Res. 2007;13(24):7250-7253.
18. Baader E, Toloczko A, Fuchs U, et al. TRAILmediated proliferation of tumor cells with receptor- close apoptosis defects. Cancer Res. 2005; 65(17):7888-7895.
19. Ehrhardt H, Haecker S, Wittmann S, et al. Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells. Oncogene. 2008;27(6): 783-793. (Pubitemid 351186307)
20. Ehrhardt H, Fulda S, Schmid I, Hiscott J, Debatin KM, Jeremias I. TRAIL induced survival and proliferation in cancer cells resistant towards TRAILinduced apoptosis mediated by NFkappaB. Oncogene. 2003;22(25):3842-3852. (Pubitemid 36819657)
21. Webb JL. Effect of more than one inhibitor. In: Hochster RM, Quastel JH, eds. Enzyme and Metabolic Inhibitors. Vol 1. New York, NY: Academic Press; 1963:487-512.
22. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28(6):622-629. (Pubitemid 46744292)
23. Mollinedo F, Gajate C. Microtubules, microtubuleinterfering agents and apoptosis. Apoptosis. 2003;8(5):413-450.
24. Yamamoto K, Ichijo H, Korsmeyer SJ. Bcl-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal kinase pathway normally activated at G2/M. Mol Cell Biol. 1999;19(12):8469-8478. (Pubitemid 30414041)
25. Basu A, Haldar S. Identification of a novel Bcl-xL phosphorylation site regulating the sensitivity of taxol- or 2-methoxyestradiol-induced apoptosis. FEBS Lett. 2003;538(1):41-47. (Pubitemid 36287422)
26. Villedieu M, Briand M, Duval M, Héron JF, Gauduchon P, Poulain L. Anticancer and chemosensitizing effects of 2,3-DCPE in ovarian carcinoma cell lines: link with ERK activation and modulation of p21WAF1/CIP1, Bcl-2 and Bcl-xL expression. Gynecol Oncol. 2007;105(2):373- 384.
27. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004; 56(2):185-229. (Pubitemid 38720829)
28. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature. 2000;408(6811):433-439.
29. Rozan LM, El-Deiry WS. p53 downstream target genes and tumor suppression: a classical view in evolution. Cell Death Differ. 2007;14(1):3-9. (Pubitemid 44911889)
30. Jänicke RU, Engels IH, Dunkern T, Kaina B, Schulze-Osthoff K, Porter AG. Ionizing radiation but not anticancer drugs causes cell cycle arrest and failure to activate the mitochondrial death pathway in MCF-7 breast cancer cells. Oncogene. 2001;20(36):5043-5053. (Pubitemid 32769794)
31. Löbrich M, Jeggo PA. The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nat Rev Cancer. 2007;7(11):861- 869.
32. Estlin EJ, Ronghe M, Burke GA, Yule SM. The clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase, anthracyclines and cyclophosphamide in relation to childhood acute lymphoblastic leukaemia. Br J Haematol. 2000;110(4):780-790.
33. Rixe O, Fojo T. Is cell death a critical end point for anticancer therapies or is cytostasis sufficient? Clin Cancer Res. 2007;13(24):7280-7287.
34. Chipuk JE, Green DR. Dissecting p53-dependent apoptosis. Cell Death Differ. 2006;13(6):994- 1002.
35. Jänicke RU, Sohn D, Schulze-Osthoff K. The dark side of a tumor suppressor: anti-apoptotic p53. Cell Death Differ. 2008;15(6):959-976. (Pubitemid 351712601)